Highbury's innovative drug research and development breakthroughs again -RVX-208 approved by the US FDA breakthrough therapy

On the evening of February 3, 2020,Shenzhen Haipu Rui Pharmaceutical Group Co., Ltd. ( 002399.SZ)Canadian subsidiaryResverlogixCorp. (Hereinafter referred to as Resverlogix) announced that its research and developmentCardiovascular and cerebrovascular drugsRVX-208 (Apabetalone) has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) (Breakthrough Therapy Designation ), which is combined with the best standard of care, including high-intensity statins, can be used for the secondary prevention of major adverse cardiovascular events in patients with type II diabetes and early acute coronary syndrome.